A Clinical Study of hiHep Cells for Bioartificial Liver After Extensive Hepatectomy
It is a prospective, non-randomized, single-arm cohort study. A total of 10 patients will be included in this study. Based on standardized treatment, the treatment of bioartificial liver device will be applied 48-72 hours after extensive hepatectomy. The bioartificial liver device consists of clinical-grade human-induced hepatocytes (hiHep) generated from human fibroblasts via transdifferentiation. In order to evaluate the security and effectiveness of the device, liver function, liver volume, the incidence of liver failure and other results will be analyzed.
• Diagnosed as liver cancer, hepatolithiasis, benign liver tumor, with clear indications for liver resection;
• Liver function Child A-B;
• There is no contraindication to surgery for cardiopulmonary function;
• The expected remaining liver volume/standard liver volume is less than 50%;